Screener
Axsome Therapeutics AXSM Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | 659,020 | 601,510 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding) | — | — |
| Common stock, $0.0001 par value per share (150,000,000 shares authorized, 51,420,445 and 50,882,766 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively) | 5 | 5 |
| Additional paid-in capital | 1,425,085 | 1,394,251 |
| Accumulated deficit | (1,370,503) | (1,305,961) |
| Total stockholders’ equity | 54,587 | 88,295 |
| Total liabilities and stockholders’ equity | $713,607 | $689,805 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's retained earnings?
- Axsome Therapeutics (AXSM) reported retained earnings of -$1.37B in Q1 2026.
- How has Axsome Therapeutics's retained earnings changed year-over-year?
- Axsome Therapeutics's retained earnings decreased by 15.9% year-over-year, from -$1.18B to -$1.37B.
- What is the long-term trend for Axsome Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Axsome Therapeutics's retained earnings has grown at a 36.2% compound annual growth rate (CAGR), from -$278.8M to -$1.31B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Axsome Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude